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Hemangiomas of Infancy: Mesenchymal Stem Cell Tumors of Perivascular Origin 
Christopher Spock 
 
Introduction: Hemangiomas of infancy (HOI) are the most common benign tumor of childhood. 
Initially thought to be composed entirely of endothelial cells, it has recently been shown that 
mesenchymal stem cells reside within these tumors. We propose that hemangiomas represent 
mesenchymal stem cell tumors of pericyte origin, as demonstrated by expression of pericytic 
markers (NG2, PDGFR-!, and DLK), neural crest origin (expression of nestin and sox10), 
expression of factors that play a role in the maintenance of stem cell pluripotency (Oct4, Sox2, 
Nanog, C-myc, and piRNAs), and a microRNA expression profile suggestive of mesenchymal 
stem cells.  
 
Methods: Quantitative RT-PCR was performed on 19 hemangioma specimens (4 proliferating, 
10 plateau, 5 involuting) analyzing transcription factors (Oct4, Sox2, C-myc, and Nanog) known 
to regulate stem cell pluripotency. Transcription factors RB, IGF2, CTCF, BORIS, DLK, and 
CDX-2 were also examined. PiRNA analysis was performed on 7 hemangioma specimens to 
investigate the role of these small RNA transcripts that interact with Piwi proteins expressed in 
the germline and stem cells. MicroRNA microarray analysis was performed on 9 hemangioma 
specimens. MicroRNA pathway analysis was performed using Ingenuity Pathway Analysis 
software and MetaCore Software. Freshly resected hemangioma specimens were cultured in 
embryonic stem cell media with and without recombinant human basic fibroblast growth factor 
(rhbFGF), recombinant human transforming growth factor ! (rhTGF-!), and 17-! estradiol.  
 
Results: All hemangiomas expressed factors RB, Oct-4, Sox-2, Nanog, C-myc, DLK, IGF-2, and 
CTCF at higher levels than endothelial cell controls. DLK, a gene that functions as a negative 
regulator of adipocyte differentiation, is increased in hemangiomas more than 10
5
 orders of 
magnitude compared to control endothelial cells. MiRNA-195, which is known to target DLK, is 
also upregulated in hemangiomas. PiRNA analysis revealed that hemangiomas do not contain 
piRNA transcripts. A microRNA microarray analysis using adult and neonatal dermal endothelial 
cells as controls indicated that microRNAs associated with mesenchymal stem cells (miR-143, 
miR320a, miR320c, let-7c) were expressed in 9 samples studied. Hemangioma growth in culture 
was not observed in embryonic stem cell media with or without supplementation with bFGF and 
TGF-!. Growth was observed in standard culture media with 17-! estradiol supplementation. 
 
Conclusion: Hemangioma specimens in all stages of growth express transcription factors and 
genes known to play a role in the maintenance of stem cell pluripotency at a level greater than 
control endothelial cells. Specifically, transcription factors Oct-4, Sox-2, Nanog, and C-myc are 
increased. Furthermore miR-143, miR320a, miR320c, and let-7c (all microRNAs identified in 
mesenchymal stem cells) are upregulated in hemangioma tissue in all stages of growth. DLK, a 
gene that functions as a negative regulator of adipocyte differentiation, is increased in 
hemangiomas compared to controls. The downregulation of this gene may lead to transformation 
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Statement of Purpose: 
 
 
Infantile hemangiomas possess interesting and complex characteristics that are 
relevant to the fields of vascular biology, stem cell biology, oncology, immunology, and 
dermatology among others. While a great deal is known about the clinical presentation 
and natural history of these lesions, the exact cell of origin and the mechanisms of 
pathogenesis of these lesions are not well understood.  
Initial theories hypothesized that hemangiomas were of placental origin. As 
important differences between hemangiomas and placental tissue were uncovered, the 
search for the cell of origin turned to endothelial cells. Increased endothelial progenitor 
cells are seen in these lesions, and other studies suggest that hemangiomas represent 
clonal expansions of endothelial cells. The composition of hemangiomas is not limited to 
endothelial cells; rather, mesenchymal stem cells play an important role in these lesions 
and may contribute to the fibro-fatty residuum left behind when these lesions involute.   
The nature of the mesenchymal stem cells in hemangiomas is not well 
understood, and neither is the relationship between mesenchymal stem cells and 
endothelial cells. Recent studies have shown that mesenchymal stem cells arise from the 
perivasculature, specifically from pericytes, and can differentiate into a variety of tissues 
including adipose. The working hypothesis of this research is that hemangiomas represent 
aberrantly differentiated mesenchymal stem cells of a perivascular location and pericyte 
lineage (CD146+, NG2+, PDGFB+, and DLK) that lead to a proliferation of endothelial 
cells due to local hypoxia and paracrine effects of secreted growth factors.  
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In order to investigate this hypothesis and classify the nature of the mesenchymal 
stem cells in hemangiomas quantitative RT-PCR was performed on hemangioma 
specimens analyzing various transcription factors (Oct4, Sox2, C-myc, and Nanog) 
known to regulate stem cell pluripotency. Additional genes and transcription factors 
known to play a role in hemangioma growth (IGF2, CTCF, BORIS, H19) were studied as 
well, to see if there was a difference between hemangiomas in various stages of growth 
compared to endothelial cell controls. Additional analysis of hemangioma specimens was 
done using a microRNA microarray. MicroRNAs are small RNAs that have emerged as 
potent regulators of gene expression. Analysis of microRNAs has been used to classify 
various cancers and to elucidate molecular pathways involved in the pathogenesis of such 
lesions. We performed a microRNA microarray assay to classify the expression profile of 
hemangiomas and to identify new pathways that could be involved in the pathogenesis 
and life cycle of hemangiomas.  
A related set of small RNAs that play an important role in stem cell pluripotency, 
known as piRNAs (named because of their interaction with Piwi-proteins) were analyzed. 
We searched for the presence of piRNAs in hemangiomas because piRNAs are associated 
with maintenance of stem cell pluripotency.  
Finally, an attempt was made to develop a new culture-based hemangioma model 
using stem cell media and specific stem cell growth factors. A better understanding of 
how the genetics of hemangiomas affects the clinical course of disease will help 





Hemangiomas of infancy (HOI) are the most common benign tumor in children. 
Historically, the nomenclature of hemangiomas has been confusing, but the classification 
system, described by Mulliken and Glowacki and refined by the International Society for 
the Study of Vascular Anomalies, provides the best framework for understanding 
hemangiomas and other vascular anomalies in infants and children.
1,2
 Within this 
framework, vascular anomalies are classified as either hemangiomas or vascular 
malformations on the basis of cellular features in relation to their clinical appearance and 
natural history. 
It is currently believed that hemangiomas are vascular tumors composed of 
hyperplastic vascular endothelial cells that have the capacity to proliferate excessively. 
Regarded as neoplasms, they grow by rapid endothelial proliferation and are 
characterized by hypercellularity.
3
 Hemangiomas are often absent or small at birth, but 
then grow rapidly in early infancy during what is known as a proliferative phase. Then, 
for an unknown reason, these tumors undergo regression and involution as part of their 
normal life cycle. As a hemangioma involutes, fibro-fatty tissue is deposited in its place,
4
 
but the origin of this tissue has yet to be determined.  
Immunohistochemical markers are used to identify hemangiomas, and GLUT1, a 
glucose transporter normally expressed in the microvascular endothelium of blood-tissue 
barriers such as brain, retina, placenta, and endoneurium, but not normal skin, is a 
specific marker for hemangiomas of infancy in all phases of development. GLUT-1 is 
strongly expressed in the entire endothelial lining of hemangioma vessels, but it is absent 
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in other vascular lesions, such as malformations, pyogenic granulomas, granulation 
tissue, as well as rapidly involuting and non-involuting congenital hemangiomas.
5
 It is 
therefore used to distinguish hemangiomas from other lesions. 
Hemangiomas are sub-classified into hemangiomas of infancy (HOI), rapidly 
involuting congenital hemangiomas (RICH), and non-involuting congenital hemangiomas 
(NICH). Both RICH and NICH present fully-developed at birth and remain static or 
rapidly involute. They are histologically and immunohistochemically distinct from HOI, 
most notably because NICH and RICH do not test positive for GLUT-1. The experiments 
described in this thesis relate specifically to hemangiomas of infancy. Therefore, the term 
hemangioma will be used to refer only to HOI and not RICH or NICH for purposes of 
clarity throughout the text. 
In contrast to hemangiomas, vascular malformations result from structural 
abnormalities of endothelial cells that are usually present at birth, are relatively mature at 
presentation, and do not exhibit a tendency towards hyperplasia with rapid proliferation. 
Vascular malformations display a normal pattern of growth, enlarge as the child grows, 
and do not spontaneously resolve. 
 
Epidemiology 
Hemangiomas of infancy are the most common tumor of childhood and affect 
between 10% and 12% of all Caucasian children.
6
 For reasons not well understood 
hemangiomas are more common in females compared with males at rates of 3:1 to 5:1.
7
 
Hemangiomas also show a predilection for the head and neck anatomic region, and in one 




Hemangiomas are more common in premature infants, and increased prevalence of 
hemangiomas correlates with both earlier gestational age and decreasing birth weight. 
9, 10
 
In addition, chorionic villus sampling (CVS) at 9 to 12 weeks of gestation has been 
associated with an increased incidence of hemangiomas in infants. In one study the 
incidence of hemangiomas was 21% with chorionic villus sampling versus 7% with 
amniocentesis.
11
 It should be noted, however, that a more recent study found no 
association with CVS.
12
 The underlying reasons for these clinical characteristics: 
preferential location on the head and neck, increased prevalence in premature infants, and 
possible association with CVS, could all be related to a hypoxic insult or stimulus as the 
triggering factor for hemangioma development. The specifics of this hypothesis are 
discussed in greater detail in the section discussing the pathogenesis of these lesions. 
 
Clinical Presentation 
On initial presentation hemangiomas typically appear as an erythematous pink or 
red macule, a blanched spot, or a telangiectasia surrounded by a pink halo.
13
 Several 
studies have documented that approximately 40% of hemangiomas are present at birth as 
a small red mark.
2,8
 The cellular composition of this early macular stage is not well 
understood. In future studies it would be helpful to biopsy these lesions in the earliest 
proliferative stages to identify the cell sub-types present, and for reasons explained later, 
to see if genes that activate in response to hypoxia are upregulated.  
 The natural history of these hemangiomas of infancy is well described and 
involves a proliferative phase early in infancy followed by an involutional phase of 
variable length occurring after the first year of life.
8
 Hemangiomas often reach their 
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maximum size by 9 to 12 months or earlier, although there is a subset that continues to 
proliferate for up to 18 to 24 months.
4
 
Involution begins as early as a few months after lesion appearance, with the usual 
onset at 12 to 18 months. The process usually begins centrally in the lesion and spreads 
peripherally. Complete involution occurs at an estimated rate of 10% per year, and a 
convenient way to remember the rate of involution is to consider that 50% have involuted 
by 5 years of age, 70% by age 7, and 90% by age 9.
4
 
During involution there is a decreased amount of endothelial cell label uptake and 
decreased number of mast cells, with the tissue being replaced by fibro-fatty stroma 
during this phase.
3
 Detailed knowledge of the clinical behavior of these lesions is 
important because it provides clues to the underlying genetic mechanisms governing 
hemangioma origin and pathogenesis, two major questions that remain to be answered 
regarding hemangiomas. Despite our clinical knowledge one of the most important areas 
of research is determining the cell of origin of hemangiomas.  
 
Hemangioma Origins – Placental Connection 
Multiple lines of evidence point to similarities between placental tissue and 
hemangiomas. The increased incidence of hemangiomas in children whose mothers had 
underwent chorionic villus sampling led initial support to this hypothesis.
11
 It was 
reasoned that the trauma of CVS increased the number of placental cells released into the 
circulation and thus increased the likelihood that these cells embolized to fetal vascular 
sites. 
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Further support of the hemangioma-placenta connection comes from the fact that 
hemangioma tissue bears striking resemblance to placental tissue. Placental vasculature 
and hemangioma tissue share expression of several surface markers. It has been 
demonstrated that both tissues express merosin, Lewis Y, Fc"RII (CD32), and glucose 
transporter 1 (GLUT-1, also expressed on endothelium of blood-brain barrier and red 
blood cells).
14,15
 Another group performed microarray analyses on placenta, hemangioma, 
and eight other normal and diseased tissues and determined that the transcriptome 
similarity between placenta and hemangioma exceeded that of any other tissue and 
mirrored that seen between normal lung parenchyma and pulmonary tumors.
16
 
Interestingly, the lifecycle of the placenta resembles that of hemangiomas. As the 
placenta develops, angiogenesis occurs at an extraordinary rate, and it is controlled by 
inhibitory factors that prevent inappropriate blood vessel growth into normal maternal 
and fetal tissue. In order to prevent uncontrolled angiogenesis the placenta produces a 
soluble form of the VEGF transmembrane receptor, sFlt-1, that is found in both maternal 
serum and amniotic fluid and serves to inhibit angiogenesis by sequestering circulating 
VEGF and placental growth factor. 
17,18
 With the passage of the placenta, the source of 
sFlt-1 is removed allowing unopposed proliferation of cells responsive to angiogenic 
growth factors. This sequence not only mirrors the natural history of hemangiomas, but it 
coincides chronologically with the appearance of infantile hemangiomas in the postnatal 
period.  
 Despite these similarities between placenta and hemangioma, the embolization 
theory is an oversimplification of the origin of hemangiomas, and there is strong evidence 
contradicting it. A study by Bree et al. demonstrated that the immunohistochemical 
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profiles of hemangiomas and placental tissue are not exactly identical. Infantile 
hemangiomas failed to stain for certain trophoblastic markers such as human placental 
lactogen, placental alkaline phosphatase, and cytokeratins 7, 8, and 11.
19
 Another study 
investigated maternal-fetal chimerism and demonstrated that hemangiomas are 
exclusively derived from the child, with no evidence of maternal origin
20
 as would be 
expected if hemangiomas were in fact embolized placenta. The similarities between 
placental tissue and hemangiomas, however, have generated new ideas regarding the 
origins of these tumors.  
 
Hemangioma Origins – Endothelial Progenitor Cells 
Recent evidence suggests that several different types of progenitor cells may play 
a role in hemangioma progression. The identity of endothelial progenitor cells is 
controversial, however, most agree that a single marker cannot identify these cells. The 
likely identity of endothelial progenitor cells comes from studies
21
 that have shown that 
cells expressing both CD34 and AC133 (CD133) can differentiate into endothelial cells 
in vitro." Normal bone marrow and peripheral blood contain such progenitor cells that 
can then differentiate into endothelial cells
22, 23
 through the process of vasculogenesis.  
Vasculogenesis occurs through a sequence of events, typically set in motion by a 
hypoxic insult to peripheral tissues which then leads to recruitment of endothelial 
progenitor cells from the bone marrow and subsequent vascular assembly. These 
endothelial progenitor cells must undergo mobilization from the bone marrow stroma, 
followed by selective homing, extravasation, differentiation, and tubule formation, 
                                                 
" For a complete listing of the cellular markers discussed in this text see Image 2. 
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ultimately leading to new blood vessel formation.
24
 Vasculogenesis is differentiated from 
angiogenesis in which the growth of new blood vessels occurs via extension and 
remodeling from existing vasculature.
25
  
The endothelial progenitor cells responsible for vasculogenesis may play an 
important role in hemangiomas as peripheral blood collected from patients with 
hemangiomas demonstrated a 15-fold increase in circulating endothelial progenitor cells. 
Those same progenitor cells also co-expressed the known hemangioma markers GLUT1, 
CD32, and merosin.
26
 Another group was able to demonstrate the presence of these 
endothelial progenitor cells in actual hemangioma specimens.
27
 Eleven of twelve 
proliferating hemangiomas in this group’s cohort demonstrated CD133+/CD34+ 
endothelial progenitor cells. However, no such cells were identified in involuting 
hemangiomas. Of note, one of the specimens in this group did not contain endothelial 
progenitor cells, which suggests that perhaps these cells do not play a role in all 
hemangiomas.  
Given this data, it is unclear if increased numbers of endothelial progenitor cells 
are the cause or effect of hemangioma formation. One postulation is that vascular 
progenitors are recruited to the hypoxic environment of hemangiomas through 
stabilization of the global regulatory protein HIF-1# and increased expression of the 
downstream effectors SDF-1# and VEGF. In addition to attracting and concentrating 
endothelial progenitor cells within the tumor, these chemokines mediate the assembly of 
progenitor cells into new vascular structures.
28
 
 The origin of the endothelial cells in hemangiomas is an important area of 
investigation. Several studies have tried to determine if hemangiomas are clonal lesions. 
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These studies examined hemangioma clonality using X-linked human androgen receptor 
gene assay (HUMARA) analysis. One study analyzed cells grown in culture from seven 
patients, and all showed a skewing toward a single allele.
29
 A subsequent study analyzed 
intact tissue without selection of cells and found some degree of allelic loss in 12 of 14 
samples.
30
 These two independent investigations suggest that hemangiomas arise as a 
consequence of clonal expansion from a single cell; however, it is possible that sampling 
constraints biased these results. It is usually only possible or practical to sample a portion 
of a hemangioma lesion and therefore conceivable that clonality accounts for only 
portions of the lesion. This argument against clonality seems even more plausible when 
one considers segmental hemangiomas, which are large and plaque-like. If these lesions 
were clonal then large numbers of cells derived from a single precursor would need to 
spread over a large anatomic area and expand simultaneously.  
 Although the clonal nature of hemangiomas is debatable it is well established that 
hemangiomas are not composed entirely of one cell type and while endothelial progenitor 
cells may play a role in these lesions, other cells should not be excluded from this 
discussion. Mesenchymal stem cells are another important population of cells isolated 
from hemangiomas, and these cells may be responsible for the unique life cycle of the 
tumor. 
 
Hemangioma Origins – Mesenchymal Stem Cells 
During involution the tissue at the site of the hemangioma develops into fibro-
adipose tissue. Little is known about the process by which this occurs, although 
mesenchymal stem cells may play a role. A group recently identified mesenchymal stem 
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cells within hemangioma tissue that are distinct from endothelial progenitor cells.
31
 This 
suggests that there are at least two distinct cell populations within hemangiomas.  
Mesenchymal stem cells are defined by their self-renewal capability and potential 
for multi-lineage differentiation into adipocytes, osteoblasts, chondrocytes, myocytes, 
neuronal cells, and hepatocytes.
32
 Mesenchymal stem cells are observed in hemangiomas 
more frequently than in normal skin, and their numbers are highest during the 
proliferative phase.
31
 Furthermore, these cells exhibit a random pattern of X-chromosome 
inactivation indicating that they are not clonally derived.
31
 The cells recovered from 
hemangiomas are found to have many of the characteristics of mesenchymal stem cells 
from other tissues, and it has been hypothesized that these cells may contribute to the 
generation of adipocytes during hemangioma involution.  
Hemangioma derived mesenchymal stem cells expressed the cell surface markers 
SH2 (CD105), SH3, SH4, CD90, CD29, smooth muscle actin, and CD133 but not the 
hematopoietic markers CD45 and CD14 or the hematopoietic/endothelial markers CD34, 
CD31.
31
 This is evidence to the fact that hemangioma derived mesenchymal stem cells 
represent a distinct population of cells from the endothelial progenitor cells 
(CD34+/AC133+) in hemangiomas of infancy. It should be mentioned that these cells 
were CD34- but flow cytometry was performed on them after they had been cultured, and 




Additional evidence linking stem cells to hemangiomas was demonstrated by 
Boscolo et al. in an experiment that isolated stem cells from hemangioma specimens and 
then injected them subcutaneously into the back of immunodeficient mice. These stem 
 17 
cells were able to differentiate and organize into functional vessels 7-14 days after 
implantation. Furthermore these vessels were CD31+/GLUT1+, and two months after 
implantation the number of blood vessels diminished and human adipocytes became 
evident.
34
 Unfortunately, the specific markers used by this group to isolate stem cells is 
not well-described in their abstract and it is unclear what specific population of cells this 
group was isolating prior to implantation. 
Until recently the origin of mesenchymal stem cells was not known. But, 
groundbreaking work has demonstrated that mesenchymal stem cells arise from the 
perivasculature and these precursor cells have the potential to develop into adipose, 
muscle, bone, and cartilage. Using lineage tracing in mice a group demonstrated that the 
precursor cells that give rise to adipocytes reside within the walls of the blood vessels 
that supply adipose tissue
35
 (See Image 1). Pericytes, the smooth muscle-like cells that 
cover the endothelial cells of blood vessels, give rise to adipocytes. These specialized 
cells express the proteins peroxisome proliferator-activated receptor $ (PPAR-$), stem 
cell antigen 1 (sca1), and CD34. This cell population also expresses smooth muscle actin 
(SMA), platelet-derived growth factor receptor-! (PDGFR-!), and neural/glial cell 2 
(NG2), which are all markers of pericytes, but not perilipin, a marker of mature 
adipocytes. Previously the only known marker of pre-adipocytes was Pref-1 (also known 
as DLK-1), a cell surface protein in the epidermal growth factor family.
36
 DLK-1 
functions as a negative regulator of adipocyte differentiation, and we hypothesize that 
this protein may play a critical role in the conversion of hemangiomas into adipose tissue. 
The identification of these adipocyte precursor cells has important implications 
regarding hemangiomas. Although Tang et al.
35
 find the PPAR-$ expressing cells only in 
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blood vessels that supply adipose tissue, pericytes isolated from other locations have 
adipogenic, myogenic, osteogenic, and chondrogenic potential.
37
 Most pericytes, 
adipocytes, myoblasts, and osteoblasts are thought to be of mesodermal origin, and in all 
four cases similar cell types in the head and neck appear to derive from neural crest.
38, 39
 
It is therefore possible that the pericyte is the cell of origin of the hemangioma. We 
hypothesize that hemangiomas of the head and neck are derived from neural crest 
pericytes (which may be uniquely sensitive to hypoxia) and that hemangiomas in other 
anatomic locations arise from mesoderm derived pericytes. 
 
Hemangioma Origins – Pericytes 
Pericytes closely encircle endothelial cells in capillaries and microvessels.
40
 
Pericytes also inhibit the division of endothelial cells via TGF-! activation.41 If one 
considers the role of pericytes in hemangiomas this could be a potential explanation for 
why hemangiomas do not become invasive secondary to uncontrolled angiogenesis.  
Pericytes can be isolated in multiple human organs including skeletal muscle, 
pancreas, adipose tissue, and placenta using CD146+, NG2, and PDGF-R! expression in 
the absence of hematopoietic, endothelial, and myogenic markers.
37
 Neural/glial cell 2 
(NG2), also known as chondroitin sulfate proteoglycan, is a proteoglycan associated with 
pericytes during vascular morphogenesis.
42
 CD146 (aka S-endo1, Mel-CAM, Muc18, or 
gicerin) is an endothelial cell antigen also expressed at the surface of pericytes.
43
 In 
addition to NG2 and CD146, all perivascular cells express PDGF-R! but do not express 
endothelial cell markers such as CD144 (VE-cadherin), von Willebrand factor (vWF), 
CD34, or CD31.
37
 The expression of PDGF-R! is of particular interest because cases of 
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familial hemangiomas have mapped to chromosome 5q31-33 which harbors the genes for 
FGF receptor 4, and PDGF-R!.44 
  The connection between mesenchymal stem cells and perivascular cells is 
strengthened by the work of Crisan et al.  This group demonstrated that mesenchymal 
stem cells are derived from perivascular cells (CD146+/NG2+/PDGF-R!+/CD34-
/CD144-/CD31-/vWF-) on the basis that these cultured perivascular cells express all 
recognized markers of mesenchymal stem cells including CD10, CD13, CD44, CD73, 
CD90, and CD105, as well as CD108, CD109 (platelet activation factor), CD140b 
(PDGFR-!), CD164, CD166, CD318, CD340 (HER-2), CD349 (frizzled-9), SSEA-4, and 
HLA-CL.
37
 Interestingly another group found that the mesenchymal stem cells isolated 
from adipose tissue express CD34 (but remain CD31-/CD45-) indicating that 
mesenchymal stem cell expression of CD34 may be rapidly down-regulated in culture.
33
 
Additional studies have shown that these multipotent mesenchymal stem cells of 
perivascular origin serve both structural and functional roles in interactions with 
endothelial cells.
33
 Mesenchymal stem cells and endothelial cells in co-culture exhibit 
preferential heterotypic assembly into vascular networks in vitro, which demonstrate a 
stability advantage in comparison with networks of endothelial cells alone. It is believed 
that paracrine interactions between these mesenchymal stem cells and endothelial cells, 
due to secreted proteins such as VEGF and bFGF, mediate this stability advantage. The 
role of secreted factors VEGF and bFGF is of particular importance because it has been 
hypothesized that the use of !-blockers in the treatment of hemangiomas of infancy 
works because of the downregulation of these specific factors.
45
 Applying this knowledge 
to hemangiomas one can hypothesize that hemangiomas represent mesenchymal stem cell 
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tumors of perivascular origin that recruit and/or direct the assembly of endothelial cells in 
response to a hypoxic insult.  
 
Mechanisms Controlling Hemangioma Growth – Role of IGF-2 
In addition to determining the cell of origin of hemangiomas much work has been 
done to elucidate the genetic mechanisms that control the growth of these lesions. In fact, 
exploration into the mechanisms controlling hemangioma growth may provide further 
insight into the cell of origin of these fascinating lesions. 
Large scale gene expression analysis of proliferating versus involuting 
hemangiomas has shown that insulin-like growth factor 2 (IGF-2) is highly expressed 
during the proliferative phase and substantially decreased during the involuting phase of 
hemangioma growth.
46
 Ritter et al. also showed that IGF-2 promotes sprouting from 
intact hemangioma tissue using a human hemangioma explant model.  
Human insulin-like growth factor (IGF-2) is an important mitogen which plays a 
role in normal fetal and postnatal growth, and also in tumorigenesis.
47
 Regulation of the 
human IGF2 gene is very complex, both at the transcriptional and post-transcriptional 
level. IGF2 lies 110-200 kb centromeric to H19
48
 a gene whose transcript is not 
translated,
49,50
 but whose molecular evolution suggests a functional role for its mRNA 
perhaps in tumor suppression. IGF2 and H19 are reciprocally imprinted, such that H19 is 
transcribed exclusively from the maternal allele, and IGF2 is transcribed from the 
paternal allele. H19 participates in the repression of IGF2, at least in part through effects 




A differentially methylated region (DMR) with paternally derived methylation is 
located 2kb upstream of H19. This region acts as an insulator when unmethylated and 
binding sites for CTCF (CCCTC-binding factor) are exposed. CTCF is a ubiquitous 11-
zinc finger protein with highly versatile functions such as transcriptional silencing or 
activating depending on the context. CTCF is also known as the Regulator of Imprinted 
Sites (RIS) because of its ability to partition DNA into active and inactive regions by 
insulating genes from proximate enhancers.
52,53
 CTCF possesses numerous recognized 
functions ranging from X chromosome inactivation to genome wide regulation, and its 
function is critical for normal cellular processes.
54-57
 Numerous studies have shown 
CTCF binding to DNA to be methylation sensitive.
58-61
 
Previous work by Narayan’s lab investigated the IGF-2/H19 locus, specifically 
looking at methylation changes in the promoter region. Analysis of methylation changes 
at this locus and sequencing has identified a C to T polymorphism
62, 63
 in this promoter 
region where CTCF binds. Narayan’s group was the first to observe that hemangiomas 
with this polymorphism had a faster time to regression.
64
 This is the first consistent 
genetic phenomenon associated with non-familial infantile hemangiomas.  
Furthermore, studies in Narayan’s lab identified a pathologic protein, BORIS 
(Brother of the Regulator of Imprinted Sites), which is normally only expressed in the 
testis.
65
 While CTCF over-expression blocks cell proliferation, expression of BORIS in 
normally BORIS-negative cells promotes cell growth that can lead to transformation.
65
 
As previously mentioned, IGF-2 is epigenetically regulated so that only the 
paternal allele is expressed in most tissues prenatally and in some tissues during postnatal 
life, a phenomenon referred to as genomic imprinting. Preferential loss of maternal alleles 
 22 
(loss of heterozygosity) and relaxation of parental imprinting (loss of imprinting) of IGF2 
occurs frequently in certain pediatric tumors such as Wilms’ tumors, adrenocortical 
carcinomas, hepatoblastomas and rhabdomyosarcomas, and in malignant adulthood 
tumors (including uterine, lung, and testicular tumors) suggesting that abnormal 
expression of IGF2 and/or of other 11p15.5 imprinted genes has a role in the 
pathogenesis of these diseases. However, a study by Yu et al. showed that loss of 




Given that a normal pattern of IGF-2 imprinting is found in hemangiomas,
66
 it is 
possible that an abnormal response to hypoxia could explain the high levels of IGF-2 in 
these lesions. Hypoxia, or low levels of oxygen, is sensed by cells, which then respond by 
modifying gene expression. Hypoxia-inducible factor 1# (HIF-1#) is a major 
transcription factor that serves as a major regulator of the cellular response to hypoxia. 
HIF-1# is involved in several cellular processes including regulation of differentiation 
and myeloid cell function,
67
 regulation of genes involved in angiogenesis, erythropoiesis, 
energy metabolism, inflammation, and cell survival.
68
 GLUT-1 and IGF-2 expression are 
both under control of HIF-1# and are induced by hypoxia.
69, 70
 
Hypoxia is a potent stimulus for neovascularization and its effects are largely 
mediated by the regulatory transcription factor hypoxia inducible factor-1# (HIF-1#). 
Increased HIF-1# activity in turn promotes expression of downstream hypoxia 
responsive genes such as vascular endothelial growth factor (VEGF) and stromal derived 
factor-1# (SCF-1#).71,72 Both VEGF and SDF-1# are critical for the recruitment, 




It has been demonstrated that proliferating hemangiomas exhibit significant 
hypoxia, leading to HIF-1# upregulation/stabilization and subsequent expression of 
downstream targets.
73
 It was also shown that in human tissues there was increased HIF-
1# expression in proliferating hemangioma samples with corresponding increases in 
VEGF and SDF-1#. Involuting samples did not demonstrate any upregulation of HIF-1#. 
The idea of a hypoxic insult leading to new vessel growth is an intriguing 
hypothesis because it has been shown that the location of hemangiomas is not random 
74
 
and may be related to areas of hypoxia. This study found that facial hemangiomas 
occurred in regions close in proximity to lines of fusion between mesenchymal growth 
centers or between mesenchymal growth centers and facial ectoderm.  Interestingly, the 
mesenchyma of the head is derived from neural crest cells.  
Neural crest-derived mesenchyma might possess unique properties that make it a 
particularly receptive field for externally derived vascular precursors. For example, it has 
been shown in chick-quail chimeras that this neurally-derived mesenchyma, unlike 
mesoderm-derived mesenchyma, has no endogenous angioblasts and must rely on 
migrating angioblasts and vascular sprouts for vascularization.
75
 Given the increased 
need for in-migration of angioblasts one can hypothesize that regions of the head may be 
subjected to areas of hypoxia due to lack of blood supply, which could then lead to 
upregulation of HIF-1#. 
 
Mechanisms Controlling Hemangioma Growth - microRNA Regulation  
The underlying mechanisms that control expression of the IGF-2/H19 locus are 
still being uncovered. One potential mechanism of regulation of this locus could involve 
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small non-coding RNAs, specifically microRNAs, which have emerged as potent 
regulators of gene expression at both the transcriptional and post-transcriptional levels.  
MicroRNAs (miRNAs), a non-coding RNA family, are 19 to 25 nucleotide (nt) 
transcripts that are cleaved from 70 to 100-nt hairpin-shaped precursors. The sequences 
of many miRNAs are conserved between distantly related organisms, suggesting that 
these molecules participate in essential processes. Although the precise biological 
functions of miRNAs are not yet fully understood, they have diverse expression patterns 
and may regulate various developmental and physiological processes. Moreover, 
dysregulation of miRNA expression might contribute to human disease. 
The first identified miRNAs, the products of the C. elegans genes lin-4 and let-7, 
have important roles in controlling developmental timing and probably act by regulating 
mRNA translation. When lin-4 or let-7 is inactivated, specific epithelial cells undergo 
additional cell divisions instead of their normal differentiation. Because abnormal cell 
proliferation is a hallmark of human cancers, it seems possible that miRNA expression 
patterns might denote the malignant state. Indeed, altered expression of a few miRNAs 
has been found in some tumor types.
76
 Several papers have recently been published that 
explore analysis of miRNAs as a way of classifying tumors.
76-78
 For example, Murakami 
et al.
78
 looked at miRNA expression to classify the degree of differentiation of 
hepatocellular carcinoma. 
Previous work by Narayan’s group identified miRNAs that would interact with 
transcription factors CTCF and BORIS. This work began as a search to identify an 
additional epigenetic control mechanism at the IGF-2/H19 gene locus. Through multiple 
prediction algorithms, a set of two related miRNAs (mir23a and mir23b) that potentially 
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target both CTCF and BORIS were identified. The implication was that miRNA could 
potentially affect imprinting. By correlating mir-23a and mir-23b to CTCF and BORIS 
levels in the hemangioma samples tested, mir-23a correlated with CTCF and BORIS 
downregulation equally well, while mir-23b correlated with CTCF downregulation. In 
addition, the difference between mir-23a and mir-23b strongly correlated with the 
difference between CTCF and BORIS. Data indicated that mir-23b could be a potential 
anti-target of BORIS relative to CTCF; thus, increased mir-23b compared to mir-23a 
expression would effectively lead to increased levels of BORIS over CTCF.  
MicroRNAs, however, serve a diverse set of functions and analysis of miRNA 
expression profiles of hemangiomas could give important insight into the molecular 
pathways involved in the pathogenesis of these lesions. Furthermore, analysis of miRNA 
expression could also give insight into the cell of origin of hemangiomas.  Several studies 
have identified populations of miRNAs that are associated with specific stem cell types. 
MicroRNAs mediate regulation of stem cell division,
79







 and hematopoietic lineages.
83
 By comparing the miRNA 
expression profile of hemangiomas to normal endothelial cell controls we hope to 
describe the specific pathways involved in the pathogenesis of these lesions.  
 
Mechanisms Controlling Hemangioma Growth – piRNA Regulation 
Assuming that hemangiomas of infancy represent tumors of stem cell origin it 
will be important to identify other potential regulators of the growth and clinical behavior 
of these lesions. Previous work by Narayan’s lab identified that hemangiomas produce 
BORIS, a pathologic protein that is normally only expressed in the testes. BORIS is a 
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member of the cancer-testis (CT) gene family that comprises genes normally expressed 
only in the testis, but abnormally activated in different malignancies. Its normal role in 
the testis consists of resetting genome-wide DNA methylation during spermatogenesis.
84
 
Hemangiomas, however, are the first benign tumor discovered to express this protein.  
Given this localization of BORIS to the testis we hypothesized that other testis-
specific regulatory proteins could be expressed in hemangiomas. Piwi proteins, a subclass 
of the family of Argonaute proteins, are expressed in germline and stem cells and they are 
associated with a unique set of small RNAs called piRNAs. 
Recently discovered piRNAs (Piwi-interacting RNAs) represent an additional 
class of small non-coding RNAs distinct from microRNAs. This class of small RNAs 
differs from small interfering RNA (siRNAs) and microRNAs (miRNAs) in several 
important ways. 
85-88
 First, piRNAs interact with the Piwi, but not the Argonaute (Ago) 
subfamily of the Piwi-Ago family proteins. Second, piRNAs are 24 to 31 nucleotides 
instead of ~21. Third, piRNAs consist of more than 50,000 different species in contrast to 
hundreds of miRNAs.  Fourth, these piRNAs are produced from long single-stranded 
precursors in contrast to siRNAs and miRNAs that are derived from double-stranded and 
short-hairpin RNA precursors, respectively. 
Most piRNAs map to unique sites in the genome, including intergenic, intronic, 
and exonic sequences. For this reason piRNAs may have diverse functions including 
epigenetic programming, repressing transposition, and post-transcriptional regulation. 
Each of these speculated roles is supported by the known function of the partner Piwi 
proteins. For instance, Piwi is an epigenetic regulator.
89
 It co-localizes with Polycomb 
group (PcG) proteins to cluster PcG response sequences in the genome.
90
 It is thus 
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possible that Piwi-associated piRNAs may be involved in epigenetic regulation. In 
addition, Piwi prevents retrotransposon transposition in the testicular germ line, which 
suggests a second role of Piwi-associated piRNAs.
91
 
The possible role of Piwi-associated piRNAs in the germline and in maintenance 
of stem cell pluripotency is what led us to further investigate the role of these RNAs in 
hemangiomas. We hypothesize that hemangiomas would express a unique pattern of 
piRNAs, the classification of which would provide further insight into the origin and 
pathogenesis of these lesions.  
 
Growth of Hemangioma in Culture 
 One of the biggest limitations to hemangioma research has been the lack of a 
viable animal model. Currently available experimental models of hemangiomas include 
induction in mice via transgenic endothelial cells,
92
 mouse endothelial cells that have 
been transformed by polyoma middle T oncogene,
93,94
 and endothelial cells obtained 
from murine and human hemangiomas.
95
 However, tumors generated from these cell 
lines have more malignant characteristics, are not obligately perinatal, and do not 
spontaneously regress.  
 An ex vivo culture system has been developed that uses intact human hemangioma 
tissue and permits biochemical manipulation.
96
 However, while this model does produce 
microvascular outgrowths in culture, the hemangioma endothelial cells are not GLUT-1 
positive.  
Additional models which use purified cultures of hemangioma-derived cells have 




 but these models lack the environmental factors found in vivo as 
potentially important growth factors, components of extracellular matrix, and direct 
influence from surrounding cells are not present. Drawbacks of this model also include a 
loss of cellular features of hemangioma endothelial cells and GLUT-1 expression. 
It is clear that hemangiomas involve a population of both endothelial cells and 
multi-potent mesenchymal stems cells of perivascular origin. It seems that the interaction 
between these two cell populations leads to the growth of hemangiomas, and a successful 
model of hemangiomas will need to incorporate this synergistic effect.  
Also of relevance to the development of a hemangioma model is the growth 
response of hemangiomas to estrogen. One group was able to demonstrate the response of 
hemangioma vascular endothelial cells to estrogen in vitro.
98
 Elevated levels of 17-! 
estradiol
99
 had previously been reported in children with hemangiomas. Xiao et al. 
demonstrated that the combination of 17-! estradiol and endothelial cell growth 
supplement in medium had a dramatic effect on proliferation of hemangioma endothelial 
cells in culture. The GLUT-1 positivity of these cells, however, was not verified. We 
hypothesize that if hemangiomas represent a population of mesenchymal stem cell 





(Performed by the student) 
All samples were collected in accordance with an approved HIC protocol 
(#0507000430) as reviewed by the Yale University Medical School IRB. As these 
samples were collected from children, fully informed parental, and childhood assent 
when age appropriate, was obtained prior to surgery. Only the tissue remaining following 
collection of the pathological specimen was used for this experiment. Specimens for 
transcriptional analysis were separated into three categories: 1) proliferative, 2) quiescent, 
and 3) involuting phases. These categories were determined on a clinical basis, as well as 
by age. Proliferative hemangiomas: Less than 1.5 years of age with interval growth 
between the last two clinic visits preceding surgery. Quiescent hemangiomas: Older than 
1 year demonstrating no interval growth between the last two clinic visits preceding 
surgery. Involuting hemangiomas: At least two years old with interval regression by 
measurement between the last two clinic visits preceding surgery. Human dermal 
microvascular endothelial cells (HDMEC), human umbilical vein endothelial cells 
(HUVEC), human adult endothelial cells, and neonatal endothelial cells were used as 
controls. 
 
RNA preservation and extraction 
(Performed by the student) 
Immediately following tissue resection, 100-500mg of tissue was minced in 10ml 
of Qiagen RNA Later solution with straight razors into pieces no larger than 1mm in any 
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dimension. Samples were stored in 50mL Falcon tubes with an additional 10mL of RNA 
Later solution. Samples were then stored at -20 degrees Celsius overnight and then frozen 
at -80 degrees Celsius until RNA extraction could be completed. RNA was extracted by 
first allowing the RNA Later solution to thaw. This was followed by straining of the 
sample and immediate liquid nitrogen powder homogenization with a mortar and pestle. 
All implements were baked at 200 degrees Celsius to eradicate RNAase enzymes. 
Following homogenization, RNA was extracted using Invitrogen Trizol reagent 
according to manufacturer’s specifications with the following exceptions. Once the initial 
phase separation was accomplished with the addition of phenol/chloroform, the samples 
were vigorously vortexed to shear genomic DNA. This helps ensure that the DNA will 
migrate completely into the organic phase instead of remaining at the inter-phase, which 
may contaminate the RNA sample. Following the phenol/chloroform extraction, the 
supernatant (aqueous RNA phase) was subjected again to a 1/24 iso-amyl-alcohol-
chloroform extraction to minimize potential phenol contamination, which could inhibit 
downstream enzymatic applications. After the isopropyl alcohol precipitation and ethanol 
washing steps, the pellets were allowed to dry for 15 to 30 minutes and were re-
suspended in nuclease free water and stored at -80 degrees Celsius. To remove potential 
genomic contamination, 10$g of total RNA from each sample was then treated with 
DNase Qiagen mini-elute columns according to manufacturer’s specifications. RNA 
integrity was then assessed using 1 $l of sample on the Agilent bioanalyzer 2100 
(provided as a service of the Keck Center at Yale University). Band intensities of 18s and 
28s RNA were quantitated and samples with an 18S/28S ratio of 1.8 or greater were 
utilized for quantitative RT-PCR. Following quality control each sample was converted 
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into cDNA using the ABI 4368813 cDNA archive kit. All samples were then stored at     
-80 degrees Celsius.  
 
5’ end-labeling of RNA for piRNA detection 
(Performed by the student) 
Dephosphorylation of RNA 
Shrimp alkaline phosphatase (SAP) dephosphorylation reaction was first 
performed on the RNA samples. The amount of sample needed for 2µg of RNA based on 
concentration was calculated.  Next the amount of H2O needed to bring the reaction 
volume up to 16.5µL was calculated. A master reaction mix of 10X SAP buffer, RNase 
Out, and SAP was made. A reaction mix of 3.5µL/tube was added for each sample 
(leaving 16.5µL for RNA and H2O). Once the reaction mix, RNA, and H2O were added 
to the tubes the reaction tubes were placed at 37˚C for 1 hour and then at 65˚C for 15 
minutes in order to inactivate the SAP. The tubes were then stored at -80˚C.  
 
5’ end-labeling of RNA 
A master mix for the end labeling reaction was made from 30µL of 10x T4PNK 
buffer, 5µL of RNase Out, 10µL of T4PNK (15U), and 55µL of H2O.  Then 10µL of 
master mix was added to each reaction tube from the dephosphorylation step bringing the 
total volume of each reaction tube to 30µL. The reaction tubes were then incubated at 
37˚C for 1 hour. Next 1.5µL of 0.5M EDTA was added to each reaction tube and the 
tubes were incubated at 65˚C for 15 minutes. The unincorporated 32-P nucleotides were 
removed by spinning the samples through Roche G25 mini quick oligo spin columns. The 
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Roche oligo columns were prepared in the following fashion: First the columns were 
allowed to warm to room temperature. The top cap was removed from each column and 
then the bottom tip was snapped off. The columns were placed in Eppendorf tubes and 
then spun at 1200x for 1 minute. The columns were then placed in clean, labeled 
Eppendorf tubes and the labeled samples were pipetted directly onto the middle of the 
matrix. The columns were then spun at 1200x for 4 minutes in order to collect the labeled 
sample in the flow-through. The columns with the unincorporated nucleotides were then 
discarded into a closed container in order to keep the ‘hot’ column matrix contained. The 
labeled flow-through was then confirmed with a Geiger counter. To each sample tube 
3µL of 6x load dye and formamide was added and the tubes were then stored at -20˚C. 
 
Running Labeled RNA on denaturing poly-acrylamide gel 
A 15% 6M urea poly-acrylamide gel was made by combining 13.125mL of 40% 
acrylamide:Bis (19:1), 12.54g urea, 3.5mL of 10x TBE and DEPC H2O to bring the final 
reaction mixture volume to 35mL. To this 35mL mixture was added 350µL of 10% APS 
and 35µL TEMED (in order to polymerize the gel). The gel was then poured between two 
cleaned glass plates and was allowed to sit for 30 minutes in order to polymerize. The gel 
was pre-run in 1x TBE in H2ODEPC for 15 minutes at 230V. The wells were flushed 
occasionally to get rid of urea. After a pre-run was completed the samples were loaded 
into the gel and were run at 230V for 2 hours (until the dye front was just above the 




Quantitative RT-PCR for CTCF, BORIS, H19, IGF-2, Oct-4, C-myc, Nanog, Sox-2, 
DLK, p16, RB, and CDX-2 
(Performed as a service by Center for Functional Genomics, Albany, NY) 
Nineteen hemangioma samples (4 proliferative, 10 quiescent, 5 involuting) and 4 
endothelial cell control lines were RNA extracted as previously specified and subjected to 
fluorescent quantitative RT-PCR using ABI Taqman primers that were previously 
validated by the manufacturer. RNA was converted to first strand cDNA by use of the 
RETROscript First Strand Synthesis Kit (Ambion, Austin, TX) and primed with oligo-dT 
according to the manufacturers specifications. Taqman gene expression assays to 
quantify gene expression were obtained from Applied Biosystems (Foster City, CA), and 
are identified below. 
 
Assay ID:   Gene Name: 
 
Hs00902008_m1  CTCF 
Hs01005963_m1  IGF2 
Hs00540744_m1  CTCF-L (BORIS) 
Hs00895526_m1  H19 
Hs00905030_m1  C-myc 
Hs02387400_g1  Nanog 
Hs01053049_s1  Sox2 
Hs03005111_g1  Oct4 
Hs00171584_m1  DLK 
Hs99999189_m1  p16 
Hs01078066_m1  RB 
Hs01078080_m1  CDX-2 
Hs99999905_m1  GAPDH 
 
Two-step Taqman-based quantitative RT-PCR was performed.  First strand cDNA 
was synthesized as described above, and the cDNA equivalent of 20 ng starting RNA was 
then included as template in qPCR reactions.  QPCR Reactions to detect gene expression 
contained 1X Taqman Master Mix (Applied Biosystems) and 1X gene-specific assay 
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reagents as recommended by the manufacturer (Applied Biosystems). All reactions were 
run in triplicate.  Reactions that did not contain template cDNA were included as 
negative controls 
Reaction plates were processed on an Applied Biosystems 7900HT Sequence 
Detection System.  The AmpliTaq Gold polymerase was activated at 95
o
C for 10 min 
followed by 40 cycles consisting of denaturation for 15 seconds at 95
o
C and annealing 
and extension for 60 seconds at 60
o
C. 
Amplification data was analyzed with the ABI Prism SDS 2.1 software (Applied 
Biosystems).  Relative quantification of gene expression was performed by the %%Ct 
method.
100
  GAPDH expression served as an endogenous control to normalize expression 
within each sample. 
The student performed data analysis in collaboration with the Yale University 
Department of Biostatistics. The nineteen cases were compared with the four controls 
using a two-sample, two tailed, t-test, assuming unequal variances.  The p-values were 
ranked and compared with the Bonferroni correction for multiple comparisons. 
Specifically, the p-values need to attain a level of significance was determined by the 
following calculation: 0.05 / 22 = .00227, where 22 equals the number of comparisons. 
 
MicroRNA Microarray 
(Performed as a service by LC Sciences, Houston, TX) 
This experiment consisted of nine hemangioma samples ages: 81, 165, 286, 299, 
380, 590, 752, 1171, and 3626 days. The ages of samples were calculated from birth to 
time of resection. In addition, two normal endothelial cell control lines were analyzed at 
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passage 4: adult and neonatal HDMEC. Each probe was included on the chip seven times 
and from these signals an average and standard deviation were calculated. P-values of the 
t-test were calculated for any detected signal for one transcript between one sample and 
another, those with values less than 0.01 were considered significant and were subjected 
to unbiased cluster analysis.  
The assay started from 2 to 5 $g total RNA sample, which was size fractionated 
using a YM-100 Microcon centrifugal filter (from Millipore) and the small RNAs (< 300 
nt) isolated were 3’-extended with a poly(A) tail using poly(A) polymerase.  An 
oligonucleotide tag was then ligated to the poly(A) tail for later fluorescent dye staining; 
two different tags were used for the two RNA samples in dual-sample experiments. 
Hybridization was performed overnight on a $Paraflo microfluidic chip using a micro-
circulation pump (Atactic Technologies). On the microfluidic chip, each detection probe 
consisted of a chemically modified nucleotide coding segment complementary to target 
microRNA (from miRBase, 11.0 http://microrna.sanger.ac.uk/sequences/) and a spacer 
segment of polyethylene glycol to extend the coding segment away from the substrate.  
The detection probes were made by in situ synthesis using PGR (photogenerated reagent) 
chemistry.  The hybridization melting temperatures were balanced by chemical 
modifications of the detection probes. Hybridization used 100 µL 6xSSPE buffer (0.90 M 
NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formamide at 34 °C.  
After hybridization, detection used fluorescence labeling, using tag-specific Cy3 and Cy5 
dyes.  Hybridization images were collected using a laser scanner (GenePix 4000B, 
Molecular Device) and digitized using Array-Pro image analysis software (Media 
Cybernetics). Data was analyzed by first subtracting the background and then 
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normalizing the signals using a LOWESS filter (Locally-weighted Regression).  For two 
color experiments, the ratio of the two sets of detected signals (log2 transformed, 
balanced) and p-values of the t-test were calculated; differentially detected signals were 
those with less than 0.01 p-values. 
Additional data analysis was performed at Yale University in the Department of 
Biostatistics. The nine cases were compared with the two controls using a two-sample, 
two tailed, t-test, assuming unequal variances.  The p-values were ranked and compared 
with the Bonferroni correction for multiple comparisons. Specifically, the p-values need 
to attain a level of significance was determined by the following calculation: 0.05 / 886 = 
.000056, where 886 equals the number of markers examined.  
 
microRNA Pathway Analysis Using Ingenuity Software and MetaCore Software 
(Performed as a service by Bioinformatics at Yale) 
Data was first analyzed through the use of Ingenuity Pathways Analysis  
(Ingenuity® Systems, www.ingenuity.com). 
 
1. Network Generation  
A data set containing gene identifiers and corresponding expression values was 
uploaded into the application.  Each gene identifier was mapped to its corresponding gene 
object in the Ingenuity Pathways Knowledge Base.  A 1.5-fold expression threshold, and 
p-value <0.05 was set to identify genes whose expression was significantly differentially 
regulated.  These genes, called focus genes, were overlaid onto a global molecular 
network developed from information contained in the Ingenuity Pathways Knowledge 
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Base.  Networks of these focus genes were then algorithmically generated based on their 
connectivity.  
  
2. Functional Analysis of an Entire Data Set  
The Functional Analysis identified the biological functions and/or diseases that 
were most significant to the data set.  Genes from the dataset that met the 1.5 fold 
expression threshold, and p-value <0.05 and were associated with biological functions 
and/or diseases in the Ingenuity Pathways Knowledge Base were considered for the 
analysis.  Fischer’s exact test was used to calculate a p-value determining the probability 
that each biological function and/or disease assigned to that data set is due to chance 
alone.    
  
3. Functional Analysis of a Network  
The Functional Analysis of a network identified the biological functions and/or 
diseases that were most significant to the genes in the network.  The network genes 
associated with biological functions and/or diseases in the Ingenuity Pathways 
Knowledge Base were considered for the analysis.  Fischer’s exact test was used to 
calculate a p-value determining the probability that each biological function and/or 
disease assigned to that network is due to chance alone.   
  
4. Canonical Pathway Analysis: Entire Data Set  
Canonical pathways analysis identified the pathways from the Ingenuity Pathways 
Analysis library of canonical pathways that were most significant to the data set.  Genes 
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from the data set that met the 1.5 fold expression threshold, and p-value <0.05 and were 
associated with a canonical pathway in the Ingenuity Pathways Knowledge Base were 
considered for the analysis.  The significance of the association between the data set and 
the canonical pathway was measured in 2 ways: 1) A ratio of the number of genes from 
the data set that map to the pathway divided by the total number of genes that map to the 
canonical pathway is displayed.  2) Fischer’s exact test was used to calculate a p-value 
determining the probability that the association between the genes in the dataset and the 
canonical pathway is explained by chance alone.  
  
5. Network/My Pathways Graphical Representation  
A network/My Pathways is a graphical representation of the molecular 
relationships between genes/gene products  (See Image 15). Genes or gene products are 
represented as nodes, and the biological relationship between two nodes is represented as 
an edge (line).  All edges are supported by at least 1 reference from the literature, from a 
textbook, or from canonical information stored in the Ingenuity Pathways Knowledge 
Base.  Human, mouse, and rat orthologs of a gene are stored as separate objects in the 
Ingenuity Pathways Knowledge Base, but are represented as a single node in the network.  
The intensity of the node color indicates the degree of up- (red) or down- (green) 
regulation.  Nodes are displayed using various shapes that represent the functional class 





Data was also analyzed using MetaCore™ software version 5.2 from GeneGo Inc.  
 
MetaCore™ is an integrated software suite for functional analysis of experimental 
data. The scope of data types includes microarray and SAGE gene expression, SNPs and 
CGH arrays, proteomics, metabolomics, pathway analysis, Y2H and other custom 
interactions. MetaCore™ is based on a proprietary manually curated database of human 
protein-protein, protein-DNA and protein-compound interactions, metabolic and 
signaling pathways and the effects of bioactive molecules in gene expression. 
MetaCore™ uses 10 different network-generating algorithms and includes specificity 
filters for tissues, functional processes, sub-cellular localization, interaction mechanisms, 
and species.  
 
Hemangioma Cell Culture 
(Performed by the student) 
Freshly resected hemangioma tissue was minced into 1mm cubes. A portion of 
the sample was placed in collagenase and incubated at 37˚ C in 5% CO2 / 95% air for 20 
minutes following mincing. Tissue sample not degraded by collagenase was divided 
equally into three parts. One portion was suspended in 100mL modified TeSR1 basal 
medium for maintenance of human embryonic stem cells (mTeSR1, StemCell 
Technologies). A second portion was suspended in 100mL mTeSR1 with the addition of 
20mL of 5x supplement (StemCell Technologies) containing recombinant human basic 
fibroblast growth factor (rhbFGF) and recombinant human transforming growth factor ! 
(rhTGF !). A third portion was suspended in 100mL mTeSR1 with the addition of 20mL 
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of 5x supplement, 10µL of basic fibroblast growth factor (bFGF, StemCell Technologies) 
with a concentration of 0.500 mg/mL, and 50µL of heparin (concentration 100ng/mL). 
These samples were then plated on a 12-well culture plate, 4 wells per sample, and 
incubated overnight at 37˚ C. The sample treated with collagenase was then divided into 
three portions as described above. One mL of each of the three collagenase samples, and 
1 mL of each of the three non-collagenase samples were then plated on a six-well 
BioFlex plate containing collagen IV membrane (Flexcell International Corp.)  This was 
then repeated on a six-well BioFlex plate containing elastin membrane (Flexcell 
International Corp).   
 Additional tissue sample was cultured according to the method published by Xiao 
et al.
98
 Tissue specimen was placed in standard culture medium consisting of Medium 
199 (M-199; Gibco, Rockville, MD) supplemented with 200µg/mL streptomycin, 
75µg/mL endothelial cell growth supplement (ECGS; Sigma, St. Louis, MO) and 
50pg/mL of 17!-estradiol (Sigma).  
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Summary of Methods: 
 
Performed by Student: 
• Specimen Collection 
• RNA extraction 
• piRNA detection 
• Hemangioma cell culture 
 
Performed as Services: 
• Quantitative RT-PCR of IGF-2, H19, BORIS, CTCF, DLK, Oct4, Sox2, Nanog, 
C-myc, CDX-2 (Center for Functional Genomics) 
• microRNA microarray (LC Sciences) 
• microRNA pathway analysis using Ingenuity Software and MetaCore Software 




Additional Experiments to Complete: 
This thesis represents a work in progress and additional experiments await completion in 
order to continue to test the hypothesis that hemangiomas represent mesenchymal stem 
cell tumors derived from pericytes. A list of anticipated experiments is below with 
appropriate explanation in the discussion section: 
 
• Confirm expression of Oct-4, C-myc, Sox-2, and Nanog with western blot 
• Examine hemangiomas for expression of nestin and sox10 (markers of neural 
crest derived cells) 
• Perform quantitative RT-PCR on samples for DLK, PDGFR-2, and NG2, PPAR-$ 
• Using a lentivirus vector treat hemangioma cell cultures with siRNA to DLK to 
show differentiation to adipocytes 
• Identify single nucleotide polymorphisms (SNPs) at the DLK gene locus. Treat 
hemangioma cell cultures with thiazolidinediones (a class of anti-diabetic drugs 
that are PPAR-$ receptor ligands and induce adipocyte differentiation) and 






Quantitative RT-PCR to Determine Expression Levels of: IGF-2, H19, CTCF, BORIS, 
Oct-4, C-myc, Sox-2, Nanog, RB, p16, DLK, and CDX-2 
We examined the transcription factors of “stemness” Oct-4, C-myc, Sox-2 and 
Nanog in 19 hemangiomas  (representing all three stages of growth) compared to control 
adult endothelial cells, neonatal endothelial cells, human dermal endothelial cells and 
human umbilical vein endothelial cells by quantitative RT-PCR. We found that all 
hemangiomas expressed factors Oct-4, Sox-2, C-myc, and Nanog at levels higher than 
endothelial cell controls (See Image 7). Taken individually these differences achieve 
statistical significance with p-values < 0.05;  (See Image 8). Because multiple 
comparisons were made, this must be taken into account using the Bonferroni correction 
(0.05/22 = 0.00227). The new threshold for significance is 0.002, and none of the stem 
cell transcription factors reach this corrected threshold for significance.  
In addition to transcription factors known to be upregulated in embryonic stem 
cells, we examined several genes implicated in the growth and pathogenesis of 
hemangiomas. These genes included IGF-2 (mitogenic, pro-angiogenic, and growth 
promoting), CTCF (universal transcription factor and regulator of IGF-2), RB (tumor 
suppressor), p16 (tumor suppressor), and DLK (negative regulator of adipogenesis and 
adipocyte maturation).   
Our results confirm the increased IGF-2 produced by hemangiomas at a 
statistically significant level of p < 0.001. IGF-2 is a pro-angiogenic and mitogenic factor 
that has been implicated in the growth of hemangiomas.
46
 The limited number of samples 
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we examined and the variability in IGF-2 production, however, prevented us from 
differentiating the level of IGF-2 production between proliferating, plateau, and 
involuting hemangioma samples. Our results also indicate that CTCF production is 
increased by a factor of 4 in hemangiomas compared to controls (p-value <0.002). This 
transcription factor binds to the IGF-2 locus and it is believed that increased levels of this 
transcription factor lead to decreased levels of IGF-2.
64
 The transcription factor BORIS 
was detectable, although at very low levels, in ten of nineteen samples. 
 RB is a widely expressed tumor suppressor protein that is dysfunctional in many 
types of cancer. An initial hypothesis predicted that this protein would be downregulated 
in hemangiomas given its role in arrest of the cell cycle. Surprisingly, the expression of 
the tumor suppressor gene retinoblastoma (RB) was increased in hemangioma samples by 
a factor of three compared to endothelial cell controls; and, this result was statistically 
significant at the p < 0.001 level.  
DLK is significant in that it represents a critical protein that is involved in the 
control of adipocyte differentiation of pre-adipocytes. A mere two-fold increase in 
expression of DLK was found to robustly prevent the conversion of 3LT3 pre-adipocytes 
to adipocytes.
36
 A previous study
46
 demonstrated a decrease in DLK expression by five 
fold during the hemangioma maturation process. The variability between our samples 
was too great to detect a significant decrease in DLK expression during the hemangioma 
maturation process. However, our results indicate that hemangiomas express DLK at a 
level greater than 10
5 
orders of magnitude compared to controls (See Image 7) and this 
result is statistically significant at the p < 0.001 level. Thus, the very high levels of DLK, 
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especially in the proliferating hemangiomas, argue for a role of this gene in the 
suppression of fat conversion.  
We also examined hemangioma samples for expression of CDX-2, a gene 
normally expressed by the placenta. Previous studies have shown that CDX-2 is 
sufficient to induce differentiation of embryonic stem cells down a trophoectoderm 
lineage, which eventually forms the placenta. Furthermore, reciprocal inhibition between 
CDX-2 in trophoectoderm and Oct3/4 in pluripotent cells is thought to be involved in 
segregation of these cell lineages.
101
 We were unable, however, to detect the placental 
specific transcription factor CDX-2 in any of our samples.  
 
PiRNA Analysis 
PiRNA analysis revealed that hemangiomas do not contain piRNA transcripts, 
thus excluding the role of these molecules in regulation of hemangioma growth and 
pathogenesis. Image 3 shows the absence of a piRNA band in all 7 hemangioma 
specimens as well as the control sample of HUVEC.  
 
MicroRNA Microarray Analysis 
Data analysis generated a list of microRNAs expressed in hemangiomas at a level 
statistically significant from the controls (adult and neonatal HDMEC). This list is 
displayed in Image 9. In addition, microRNA profiles of the 9 samples and 2 controls 
were clustered (average linkage, correlation similarity). The results of this analysis are 
displayed in Images 11 and 12. However, when the microRNA expression profiles of the 
three proliferating hemangioma samples were compared to the three involuting samples 
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there was no statistically significant difference in expression profiles. The reason for this 
may be attributable to our small sample size and the large number of microRNAs 
analyzed. Given the large number of comparisons made between specimens and controls, 
results required a p-value of < 0.000056 in order to attain significance, when using the 
Bonferroni correction (0.05/886 = 0.000056).  
Despite this high threshold for significance, our microarray data indicates that 
microRNAs associated with mesenchymal stem cells (miR-143, miR320a, miR320c, let-
7c) are upregulated in hemangiomas compared to controls. Of particular interest, miR-
143 was significantly upregulated in this group of tumors by over 100x compared to 
controls (p< 0.000056). Increased levels of miR-143 have been observed in 
differentiating adipocytes, and inhibition of miR-143 has been shown to effectively 
inhibit adipocyte differentiation.
80
 MiRNA 195, a microRNA known to target DLK, was 
also upregulated more than 25x in hemangioma samples.  
Both let-7c and let-7g have increased expression levels in hemangiomas 
compared to controls. Let-7g is upregulated 2x and let-7c is upregulated 1.5x in 
hemangiomas compared to controls (p<0.000056). Let-7 was originally identified in C. 
elegans in a screen seeking genes that regulate developmental timing.
102
 Loss of function 
of this miRNA prevents normal transition of late larval to adult cell fates. There are 12 
let-7 homologs in the human genome, organized in eight distinct clusters. At least four of 
these clusters are contained within regions known to be frequently deleted in diverse 
human malignancies.
103
 Furthermore, two studies have documented frequent 





Analysis of hemangioma specimens also revealed decreased expression of miR-
106a by 2x compared to controls. The retinoblastoma (RB1) 3’UTR is found to be 
functionally interactive with miR-106a.
106
 The biological significance of this proven 
miRNA::mRNA interaction is reinforced by previous reports showing that RB1 gene is 
normally transcribed in colon cancers whereas various fractions of cells do not express 
RB1 protein.
107
 This finding suggests a post-transcriptional mechanism for regulation of 
RB1, which could possibly be explained by the concomitant overexpression of miR-106a 




MicroRNA Pathway Analysis 
Ingenuity software helped identify key molecules and pathways that could 
potentially play a role in the pathogenesis of hemangiomas. Of 603 microRNAs in the 
initial list 466 were recognized by Ingenuity and 150 were eligible for network analysis. 
With a 1.5-fold expression threshold and p-value <0.05, 65 miRNAs were network 
analysis eligible. The top biological functions implicated in hemangioma pathogenesis 
were cancer and reproductive system disease. Both the cardiovascular and nervous 
systems were implicated as developmental systems involved in hemangioma 
pathogenesis. A complete list is shown in Image 13.  
When these biological functions are organized into networks and then ranked 
according to the –log of the p-value, the network that includes cancer, reproductive 
system disease, cellular growth and proliferation is most significantly involved. A 
complete list of the networks implicated in hemangioma pathogenesis is shown in Image 
14.  
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 The Cancer, Reproductive System Disease, Cellular Growth and Proliferation 
Network is displayed in the appendix (See Image 15).  In-depth analysis of these 
networks falls outside the scope of our hypothesis because the vast majority of 
transcription factors and miRNAs pictured have yet to be directly linked to 
hemangiomas. However, this image is included to demonstrate the data generated by this 
analysis and to show how the creation of such networks can elucidate the transcription 
factors and second messengers that function as downstream targets of the miRNAs 
differentially expressed in hemangiomas. The identification of key pathways involved in 
hemangioma pathogenesis will prove to be important in developing new therapeutics that 
more specifically target hemangiomas than the ubiquitously prescribed corticosteroids 
that now comprise the mainstay of treatment for these lesions. 
Pathway analysis was also performed using MetaCore software and the results of 
this analysis are more directly relevant to evaluation of our hypothesis that hemangiomas 
represent tumors of mesenchymal stem cell origin. The MetaCore software generates 
networks centered on specific transcription factors and suggests which transcription 
factors regulate the indicated genes. Members of the target list are shown with a blue or 
red circle next to their icons, where red indicates upregulation and blue indicates 
downregulation in the experiment. Red lines indicate inhibition, and green lines 
activation, as indicated from the literature.  
Image 16 shows the relationship between C-myc and numerous miRNAs. Of the 
miRNAs pictured only let-7c and let-7a-1 regulate C-myc expression, and both have an 
inhibitory effect. The rest of miRNAs depicted are downstream targets of C-myc. Similar 
images are generated for p53 and Sox2 (See Image 17). These images show how the 
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differentially expressed microRNAs in hemangiomas interact with various other 
transcription factors.  
 Another function of MetaCore allows for Interactome analysis, which was 
performed with the miRNA genes that were 1.5x upregulated (at p<0.05), and combined 
with genes implicated in hemangioma pathogenesis. This analysis begins by identifying 
genes found in the literature or reported in the MetaCore disease database as associated 
with hemangiomas (See Image 18). These genes were then added to the miRNA gene set 
to strengthen the network analysis.  
The Interactome analysis table (See Image 19) shows transcription factors having 
a significantly high number of outgoing connections (i.e., connections of the type 
“regulates”) to members of the target list. The False Discovery Rate parameter for the list 
was set at 0.05 (i.e. 1 out of 20 are likely false). Those transcription factors that have a 
small number of connections (like r=1) to list members are the least reliable ones. 
Image 21 shows a network of miRNAs and known hemangioma related genes. 
This is most useful image in highlighting the key molecules involved in the regulation of 
hemangioma-related genes. The threshold for differential expression of miRNA is set to 
4x in order to increase the specificity of the pathways highlighted. Image 22 highlights 
the shortest pathway between hemangioma related genes and differentially expressed 
miRNAs.  
MetaCore then uses the list of differentially expressed miRNAs and a list of 
known hemangioma genes derived from the scientific literature to develop a list of 
disease processes that share biomarkers with hemangiomas. The results of this analysis 
are displayed in Images 23 and 24.  Image 23 uses only the list of differentially expressed 
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miRNAs, while Image 24 combines these miRNAs with known hemangioma related 
genes.  
Similarly to Ingenuity, MetaCore identified uterine neoplasms and disease as the 
processes sharing most pathways and biomarkers with hemangiomas. Image 25 gives a 
graphical representation of the pathways shared by hemangiomas and uterine disease and 
the key players in these pathways. As highlighted miR-21 and let-7a-1 are both involved 
as well as the transcription factors CTCF, BORIS, and C-myc, all of which exert 
influence on IGF-2, a key regulator of hemangioma proliferation and growth. 
 
Hemangioma Cell Culture 
None of the hemangioma tissue specimens placed in embryonic stem cell medium 
demonstrated growth or vascular sprouting in culture after incubation for seven days. The 
hemangioma tissue that was placed in standard culture medium supplemented with 
200µg/mL streptomycin, 75µg/mL endothelial cell growth supplement demonstrated 
growth at the one-week mark.  Growth became prominent at the 2-&  week mark.  
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Summary of Results: 
 
• Hemangiomas express the stem cell related transcription factors Oct-4, Sox-2, C-
myc, and Nanog at levels higher than endothelial cell controls. This is significant 
at the p < 0.05 level but not at the 0.002 level required by the Bonferroni 
correction for multiple comparisons. 
 
• Hemangiomas express IGF-2, RB, and DLK at a level higher than endothelial cell 
controls (p < 0.001). 
 
• Hemangiomas do not express the placental transcription factor CDX-2. 
 
• Hemangiomas do not contain piRNA transcripts. 
 
• Hemangiomas express the following miRNAs (miR-143, miR320a, miR320c, let-
7c) that are associated with mesenchymal stem cells at levels higher than controls 
(p < 0.000056). 
 
• miR-143 is upregulated in hemangiomas more than 100x compared to controls (p 
< 0.000056). Increased levels of miR-143 have been observed in differentiating 
adipocytes and inhibition of miR-143 has been shown to effectively inhibit 
adipocyte differentiation. 
 
• miR-195, known to target DLK, is upregulated more than 25x compared to 
controls (p < 0.000056).  
 
• Embryonic stem cell media supplemented with recombinant human basic 
fibroblast growth factor (rhbFGF) and recombinant human transforming growth 











Hemangioma Placenta Connection 
While it is no longer believed that hemangiomas represent embolized placental 
tissue, the similarities between the two tissues should help us think about hemangiomas 
as tumors composed of cells performing a barrier function. Just because hemangiomas 
are not placental tissue does not mean that we should abandon investigation process into 
the overlap between them. Two independent microRNA pathway analysis programs, 
Ingenuity and MetaCore, identified reproductive system disease (Uterine Disease in 
MetaCore) as an important network regulated by microRNAs differentially expressed by 
hemangiomas (See Images 15 and 25). MicroRNA 21 is predicted to be a critical player 
in both of these networks, and microarray analysis shows upregulation of this molecule in 
hemangiomas of all stages of growth. 
A potential oncogenic role for miR-21 was first discovered in a screen for 
abnormally expressed miRNAs in glioblastoma.
108
 Using an expression array and 
northern blotting, miR-21 was demonstrated to be consistently upregulated in human 
glioblastoma tumor tissues, primary tumor cultures, and established glioblastoma cell 
lines relative to normal fetal and adult brain tissue and primary cultured neurons and 
astrocytes. Knockdown of miR-21 in glioblastoma cell lines led to activation of caspases 
and a corresponding induction of apoptotic cell death. Support for a more general role of 
miR-21 in cancer was recently observed with widespread overexpression of miR-21 in 





Our research has uncovered further differences between placental tissue and 
hemangiomas with the fact that hemangiomas do no express the placental specific 
transcription factor CDX-2. This transcription factor is involved in the differentiation of 
embryonic stem cells down a trophoectoderm lineage,
101
 which eventually develops into 
the placenta. The question still remains why do hemangiomas share so many markers 
with placental tissue? The answer to this may lie in the fact that placental tissue contains 
a large population of pericytes. 
 Additional connections between placental tissue and hemangiomas remained to be 
discovered. Previous work by Narayan’s lab identified that hemangiomas express the 
pathologic protein BORIS, which is normally only expressed in the testis. BORIS is a 
member of the cancer-testis (CT) gene family that comprises genes normally expressed 
only in testis, but abnormally activated in different malignancies. Its normal role in the 
testis consists of resetting genome-wide DNA methylation during spermatogenesis. 
Given this localization of BORIS to the testis, we hypothesized that other testis-specific 
regulatory proteins, specifically piRNAs, could be expressed in hemangiomas. However, 
our results indicate that piRNAs are not present in hemangiomas and therefore do not 
play a role in the growth or pathogenesis of these lesions.  
 
Hemangiomas as Mesenchymal Stem Cell Tumors 
It has long been thought that hemangiomas are endothelial cell tumors. One group 
has shown that endothelial progenitor cells are present in hemangiomas.
27
 However, not 
all samples (eleven of twelve) demonstrated CD133+/CD34+ endothelial progenitor 
cells. Furthermore, no such endothelial progenitor cells were identified in involuting 
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hemangiomas. If hemangiomas were in fact endothelial cell tumors, one would expect all 
hemangioma specimens to contain endothelial progenitor cells, cells which are present at 
the start of the tumor and persist throughout the lifecycle of the tumor.  
These studies examined hemangioma clonality using X-linked human androgen 
receptor gene assay (HUMARA) analysis. One study analyzed cells grown in culture 
from seven patients, and all showed a skewing toward a single allele.
29
 A subsequent 
study analyzed intact tissue without selection of cells and found some degree of allelic 
loss in 12 of 14 samples.
30
 These two independent investigations suggest that 
hemangiomas arise as a consequence of clonal expansion from a single cell, however, it 
is possible that sampling constraints biased these results. It is notable that 2 of the 14 
samples did not show allelic loss, an argument against endothelial cell clonality in 
hemangiomas.  
It was recently demonstrated that a population of stem cells exist within 
hemangiomas.
31
 These cells, termed hemangioma mesenchymal stem cells (Hem-MSCs), 
were isolated from 14 proliferating and five involuting hemangiomas by taking advantage 
of mesenchymal stem cells’ selective adhesion to plastic bacteriologic dishes.
32
 These 
Hem-MSCs exhibited a random pattern of X-inactivation indicating that these cells are 
not clonally derived. Authors of this study hypothesized that these mesenchymal stem 
cells originated in the bone marrow and through selective homing arrived at the site of 
the developing hemangioma. A recent lineage study shows, however, that pericytes are 
the source of these mesenchymal stem cells.
35
 
Even more intriguing is the possibility that the endothelial cells present in 
hemangiomas arise from mesenchymal stem cells. If this were the case, a single cell type 
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could explain the pathogenesis of these lesions. One group identified a population of cells 
(CD34+/CD31-/CD45-) from the stromovascular portion of adipose tissue that could 
differentiate into endothelial cells.
109
  Another group found a similar population of cells 
(CD31-/CD34-/CD106-/VCAM-/fetal liver kinase+) from adipose tissue that expressed 
endothelial markers when cultured with VEGF.
110
 Given that this population of 
mesenchymal stem cells can differentiate into endothelial cells the causative defect in 
hemangiomas may reside within this population of cells which then gives rise to a 
proliferation of endothelial cells.  
Even if mesenchymal stem cells are not the source of cells that differentiate into 
endothelial cells, additional studies have shown that these multipotent mesenchymal stem 
cells of perivascular origin serve both structural and functional roles in interactions with 
endothelial cells.
33
 Hemangiomas may proliferate as a result of the unique interaction 
between mesenchymal stem cells and endothelial cells in response to hypoxia in the local 
environment or other potential causes.   
By using quantitative RT-PCR, we demonstrated that hemangiomas specimens 
express transcription factors and genes known to play a role in the maintenance of stem 
cell pluripotency at a level greater than control endothelial cells. Specifically, 
transcription factors Oct-4, Sox-2, C-myc, and Nanog are increased. This corroborates an 
earlier study that identified mesenchymal stem cells within hemangioma tissue that are 
distinct from endothelial progenitor cells.
31
  





 C-myc, and Nanog
114
 as factors that play a role in the maintenance 
of pluripotency in both early embryos and embryonic stem cells. These factors were 
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selected for analysis because Takahashi and Yamanaka demonstrated that adult fibroblast 
cells can be reprogrammed into pluripotent stem cells by the induction of four critical 
factors: Oct3/4, Sox2, C-myc, and Klf4.
112
 In addition, Oct4 plays a critical role in the 
establishment and maintenance of pluripotent cells in a pluripotent state.
115
  
Expression of Sox2, Oct-4, Nanog, and C-myc at levels higher than control 
endothelial cells does not confirm that hemangiomas represent tumors derived solely 
from mesenchymal stem cells. However, the expression of these factors does confirm that 
there is a population of stem cells within hemangioma tissue and gives further evidence 
to the role of this population of cells within hemangiomas.  
A microRNA microarray lends further support to this hypothesis. A previous 
study
116
 has identified a set of microRNAs associated with mesenchymal stem cells. Of 
these miRNAs our analysis indicates that miR-143, miR320a, miR320c, and let-7c (all 
identified in mesenchymal stem cells) are upregulated in hemangioma tissue in all stages 
of growth.  
Given that a population of mesenchymal stem cells 
(SH2+/CD105+/SH3+/SH4+/CD90+/CD29+/smooth muscle #–actin+/CD133+/CD45-
/CD14-/CD34-/CD31-)" exists within hemangiomas, it is important to better characterize 
the nature of these cells. The first step towards this will be identifying the specific cell 
markers of this population of cells. To date the best method for identifying the pluripotent 
stem cell population found in the stromovascular portion of adipose tissue is using the 
profile: CD34+/CD31-/CD45-/CD144-, and 95% of this population of cells co-express 
mesenchymal cell markers (CD10, CD13, CD90) and surface markers used to identify 
                                                 
" The CD34 positivity of this population of cells is uncertain because it has been shown that CD34+ is 
downregulated in culture (117).  
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pericytes (NG2 and PDGFR).
33
 In future experiments it will be helpful to try and isolate 
this specific population of cells from hemangiomas.  
 
Pericytes are the origin of mesenchymal stem cells 
We are just beginning to understand the relationship between pericytes and 
mesenchymal stem cells. Recently, it has been demonstrated that pericytes are the 
population of cells that give rise to mesenchymal stem cells that then develop into 
adipocytes.
35
 It stands to reason that if hemangiomas are mesenchymal stem cell tumors, 
then they have likely developed from pericyte origins. At the time of completion of this 
thesis experiments to examine the recognized markers of pericytes (PDGFR and NG2) in 
hemangioma specimens are pending.  Hemangioma pathologic specimens will be stained 
for PDGFR and NG2 as well.  
Pericytes of the head and neck are derived from neural crest while pericytes in the 
rest of the body derive from mesoderm. In order to investigate the potential neural crest 
origins of hemangiomas we plan to analyze samples for nestin and sox10, which are 
considered to be the best markers of neural crest-derived cells.  
 
 
Regulation of Adipogenesis in Hemangiomas 
As we begin to develop an understanding of the role of mesenchymal stem cells in 
hemangiomas, it is important to identify those genes responsible for the progression and 
development of the tumor. One gene that holds great promise is DLK, also known as 




functions as a negative regulator of adipocyte differentiation. A previous study has shown 
that DLK is decreased five fold during the hemangioma maturation process.
46
 Our results 
confirmed that DLK is increased in hemangiomas compared to controls, but there was too 
much variability between groups to say with certainty whether DLK expression is 
decreased in involuting hemangiomas compared to proliferating specimens. 
The results of our microRNA microarray also show that miR-143 is increased in 
hemangiomas compared to controls. This is of particular interest because increased levels 
of miR-143 were observed in differentiating adipocytes, and inhibition of miR-143 has 
been shown to effectively inhibit adipocyte differentiation.
80
  
DLK may be a potential therapeutic target in the treatment of hemangiomas. 
Downregulation of DLK, possibly through the use of siRNA, could hasten the 
development of hemangiomas into fibroadipose tissue. In order to test this hypothesis we 
plan to treat hemangioma cell cultures with siRNA to DLK using a lentivirus vector, to 
determine if this speeds progression of cells into adipose tissue.  
Along these lines of investigation we also plan to identify single nucleotide 
polymorphisms at the DLK gene locus. Freshly resected hemangioma specimens will be 
genotyped for these polymorphisms and then grown in culture. Once in culture, samples 
will be treated with thiazolidinediones, a class of anti-diabetic drugs that are peroxisome 
proliferator-activated receptor $ (PPAR-$) ligands that induce adipocyte differentiation 
and increase the expression of PPAR-$ protein. We will then measure time to conversion 







The results of our investigation do not conclusively implicate mesenchymal stem 
cells as the cells of origin of hemangiomas. However, we have demonstrated that 
hemangiomas express genes involved in the maintenance of stem cell pluripotency and 
express microRNAs transcripts that are markers of mesenchymal stem cells at a level 
significantly greater than endothelial cell controls. Important pieces of evidence are still 
necessary to prove or disprove our hypothesis and several of these experiments are 
pending. We must demonstrate that hemangiomas express markers of pericytes (NG2, 
PDGFR-!). We must demonstrate that hemangiomas on the head and neck are of a neural 
crest origin. Most importantly we must isolate the implicated cells of origin and show 
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Also known as Pref-1, marker of pre-adipocytes, and cell 
surface receptor in the epidermal growth factor family 
Glut-1 
Glucose transporter normally expressed in the 
microvascular endothelium of blood-tissue barriers such as 
brain, retina, placenta, and endoneurium 
NG2 
Neural/glial cell 2, also known as chondroitin sulfate 
proteoglycan, is a proteoglycan associated with pericytes 
during vascular morphogenesis; a marker of pericytes 
PDGFR 
Platelet derived growth factor receptor, a marker of 
pericytes 
PPAR-gamma Expressed by pericytes and adipocytes 
sFlt-1 
Soluble form of the VEGF transmembrane receptor 
SH2 
Also known as CD105, a surface marker of hemangioma 
derived MSCs along with SH3, SH4, CD90, CD29, CD133, 
smooth muscle actin 
CD14 Hematopoietic marker 
CD31 Hematopoietic/endothelial marker 
CD34 
Marker of endothelial progenitor cells along with CD133, 
also found on MSCs; downregulated in culture  
CD45 Hematopoietic marker 
CD133 
Also known as AC133, a marker of endothelial progenitor 
cells along with CD34 
CD146 
Also known as S-endo1, Mel-CAM, Muc18, or gicerin, an 








Sample Age in Days RE +/- 
Adult Endothelial Control 0 1.00 0.02 
Neonatal Endothelial Control 0 0.99 0.02 
Human Umbilical Vein Endothelial Control 0 1.19 0.07 
Human Dermal Endothlelial Control 0 1.4 0.29 
Proliferating Hemangioma 81 2.05 0.04 
Proliferating Hemangioma 95 6.54 0.27 
Proliferating Hemangioma 95 3.61 0.32 
Proliferating Hemangioma 165 1.91 0.06 
Plateau Hemangioma 286 2.63 0.02 
Plateau Hemangioma 299 2.87 0.33 
Plateau Hemangioma 380 1.93 0.07 
Plateau Hemangioma 418 7.06 0.33 
Plateau Hemangioma 420 6.39 0.22 
Plateau Hemangioma 547 6.36 0.41 
Plateau Hemangioma 590 1.81 0.20 
Plateau Hemangioma 635 6.7 0.18 
Plateau Hemangioma 752 1.85 0.11 
Plateau Hemangioma 760 7.33 0.65 
Involuting Hemangioma 1171 1.83 0.46 
Involuting Hemangioma 1277 1.34 0.06 
Involuting Hemangioma 1520 4.02 0.57 
Involuting Hemangioma 2138 0.5 0.02 
Involuting Hemangioma 3626 4.18 0.34 
!"#$%&'())*+,# -./#$%&'())*+,#
Sample Age in Days RE +/- 
Adult Endothelial Control 0 1.00 0.03 
Neonatal Endothelial Control 0 0.52 0.03 
Human Umbilical Vein Endothelial 
Control 0 0.00 0.00 
Human Dermal Endothlelial 
Control 0 0.00 0.00 
Proliferating Hemangioma 81 308974.72 11193.45 
Proliferating Hemangioma 95 70988.3 3396.23 
Proliferating Hemangioma 95 153060.6 10311.93 
Proliferating Hemangioma 165 596991.60 24691.21 
Plateau Hemangioma 286 369600.56 14907.02 
Plateau Hemangioma 299 1119257.50 153168.75 
Plateau Hemangioma 380 214070.92 8838.76 
Plateau Hemangioma 418 69511.45 2480.54 
Plateau Hemangioma 420 81457.12 2784.75 
Plateau Hemangioma 547 64348.36 2082.9 
Plateau Hemangioma 590 164881.06 22057.23 
Plateau Hemangioma 635 126015.95 7204.07 
Plateau Hemangioma 752 567857.56 35369.21 
Plateau Hemangioma 760 43438.04 1599.01 
Involuting Hemangioma 1171 716259.50 176958.58 
Involuting Hemangioma 1277 94.47 16.14 
Involuting Hemangioma 1520 31124.69 1053.16 
Involuting Hemangioma 2138 2330.59 165.33 
Involuting Hemangioma 3626 560208.30 56309.02 
$%&'())*+,#+0#1234+')#!"#2,5#-./#2)#-(4('6*,(5#78#9:2,;42;<(#!=>?@!#
A#
Sample Age in Days 
Oct4 Sox2 Nanog C-Myc 
RE +/- RE +/- RE +/- RE +/- 
Adult Endothelial Control 0 1.00 0.04 1.00 0.10 1.00 0.12 1.00 0.06 
Neonatal Endothelial Control 0 0.41 0.04 0.00 0.00 0.78 0.03 1.88 0.04 
Human Umbilical Vein Endothelial Control 0 14.72 1.64 195.26 7.79 29.4 2.1 0.00 0.00 
Human Dermal Endothlelial Control 0 2.45 1.06 0.00 0.00 0.00 0.00 0.00 0.00 
Proliferating Hemangioma 81 19.45 1.08 25.24 5.99 94.17 4.17 6.49 0.16 
Proliferating Hemangioma 95 73.16 8.08 575.63 85.44 381.83 44.39 1.00 0.02 
Proliferating Hemangioma 95 91.97 8.73 396.01 133.29 237.28 18.88 0.00 0.00 
Proliferating Hemangioma 165 9.43 0.46 11.22 1.28 88.24 4.82 0.00 0.73 
Plateau Hemangioma 286 15.96 0.57 74.31 9.72 282.30 6.85 12.23 0.12 
Plateau Hemangioma 299 19.18 2.55 20.96 2.56 176.75 21.05 8.76 1.08 
Plateau Hemangioma 380 4.34 0.09 295.36 12.48 45.27 3.95 5.76 0.07 
Plateau Hemangioma 418 90.6 14.54 249.72 48.03 264.62 11.99 1.17 0.09 
Plateau Hemangioma 420 27.17 2.04 0.00 0.00 658.75 42.09 1.88 0.03 
Plateau Hemangioma 547 0.00 0.00 1787.73 247.59 336.11 36.82 0.78 0.04 
Plateau Hemangioma 590 78.65 4.27 0.00 0.00 2012.48 156.71 35.65 3.07 
Plateau Hemangioma 635 337.05 51.12 882.22 28.58 3072.5 165.83 0.00 0.00 
Plateau Hemangioma 752 18.06 1.10 78.30 9.29 127.31 7.69 4.13 0.25 
Plateau Hemangioma 760 107.94 16.56 442.11 108.44 697.57 39.62 1.77 0.08 
Involuting Hemangioma 1171 32.69 8.19 104.41 27.44 392.09 95.60 12.92 3.21 
Involuting Hemangioma 1277 8.61 0.96 511.79 63.8 14.96 0.74 0.36 0.01 
Involuting Hemangioma 1520 47.69 5.91 327.01 88.11 453.72 8.66 0.62 0.03 
Involuting Hemangioma 2138 6.53 0.58 963.52 137.96 33.11 0.95 0.03 0.00 




Sample Age in Days 
IGF-2 CTCF H19 BORIS 
RE +/- RE +/- RE +/- RE +/- 
Adult Endothelial Control 0 1.00 0.05 1.00 0.04 0.00 0.00 0.00 0.00 
Neonatal Endothelial Control 0 0.42 0.01 0.86 0.03 0.00 0.00 0.00 0.00 
Human Umbilical Vein Endothelial Control 0 16.46 2.02 3.32 0.17 0.00 0.00 0.00 0.00 
Human Dermal Endothlelial Control 0 0.16 0.05 2.49 0.22 0.00 0.00 0.00 0.00 
Proliferating Hemangioma 81 11175.69 244.15 2.94 0.06 1.35 0.09 0.07 0.00 
Proliferating Hemangioma 95 5340.17 513.55 9.64 0.18 0.00 0.00 0.00 0.00 
Proliferating Hemangioma 95 6310.24 144.79 10.57 0.41 0.00 0.00 0.00 0.00 
Proliferating Hemangioma 165 7008.52 197.56 2.81 0.08 0.40 0.02 0.40 0.01 
Plateau Hemangioma 286 7104.24 179.33 3.99 0.05 0.29 0.05 1.01 0.07 
Plateau Hemangioma 299 9342.13 1080.98 7.41 0.93 1.00 0.23 1.00 0.17 
Plateau Hemangioma 380 3725.51 151.69 2.83 0.08 0.17 0.03 0.75 0.13 
Plateau Hemangioma 418 8038.53 228.03 31.7 1.59 0.00 0.00 0.00 0.00 
Plateau Hemangioma 420 12583.25 209.86 13.2 0.51 0.00 0.00 0.00 0.00 
Plateau Hemangioma 547 6505.15 215.46 0.00 0.00 0.00 0.00 0.00 0.00 
Plateau Hemangioma 590 32721.81 2518.83 6.30 0.41 0.25 0.00 0.00 0.00 
Plateau Hemangioma 635 11762.76 972.26 16.68 0.71 0.00 0.00 0.79 0.09 
Plateau Hemangioma 752 10283.14 585.44 3.42 0.29 0.18 0.01 0.77 0.20 
Plateau Hemangioma 760 11517.89 341.06 15.92 1.09 0.00 0.00 0.5 0.05 
Involuting Hemangioma 1171 13263.79 3242.72 8.51 2.08 0.86 0.23 0.77 0.20 
Involuting Hemangioma 1277 29.93 1.49 2.73 0.13 0.00 0.00 0.00 0.00 
Involuting Hemangioma 1520 1162.69 35.52 7.46 0.52 0.00 0.00 0.00 0.00 
Involuting Hemangioma 2138 66.49 3.2 1.48 0.06 0.00 0.00 0.00 0.00 







control N Mean Std. Deviation 
Std. Error 
Mean 
RB Expression sample 19 3.7321 2.27742 .52248 
control 4 1.1450 .19330 .09665 
p16 Expression sample 19 3.2800 1.76556 .40505 
control 4 2.4925 2.43641 1.21820 
DLK Expression sample 19 276866.9100 3.04586E5 69876.81214 
control 4 .3800 .48056 .24028 
Oct4 Expression sample 19 53.5305 76.54509 17.56065 
control 4 4.6450 6.77114 3.38557 
Sox2 Expression sample 19 371.7595 447.44164 102.65015 
control 4 49.0650 97.46447 48.73224 
Nanog Expression sample 19 510.9995 762.19721 174.86003 
control 4 7.7950 14.40972 7.20486 
C-myc Expression sample 19 5.2095 8.43447 1.93500 
control 4 .7200 .90569 .45284 
Igf2 Expression sample 19 9427.1426 7615.04047 1747.01010 
control 4 4.5100 7.97440 3.98720 
CTCF Expression sample 19 8.5926 7.61084 1.74605 
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hsa-miR-320c 2,523 2,099 2,227 2,051 5,116 1,813 2,091 2,444 2,168 8,777 9,007 
hsa-miR-299-5p 71 143 72 100 148 70 119 111 150 323 319 
hsa-miR-320a 2,729 2,261 2,343 2,073 5,792 1,884 2,258 2,368 2,174 9,048 9,384 
hsa-miR-106a 1,466 771 920 1,078 876 1,259 661 1,505 1,244 2,430 2,392 
hsa-miR-126 33,777 27,775 31,183 31,147 37,147 34,761 30,094 33,915 30,145 18,571 17,781 
hsa-miR-517a 15,488 14,731 11,029 14,639 13,220 7,615 12,725 11,341 15,407 106 229 
hsa-miR-517b 13,095 11,903 9,829 12,034 12,860 6,421 11,051 9,261 13,233 132 250 
hsa-miR-195 17,463 16,937 18,984 16,854 8,154 19,179 15,630 17,371 16,912 529 605 
hsa-miR-152 1,734 1,140 1,756 1,508 1,650 2,025 1,352 1,529 1,334 433 401 
hsa-miR-1308 5,567 3,043 2,355 682 2,504 461 7,489 297 1,689 14,134 13,322 
hsa-miR-143 16,484 12,837 18,717 15,233 25,105 16,051 12,195 13,961 14,998 51 230 
hsa-miR-151-3p 780 361 682 408 1,117 434 467 472 471 1,856 1,758 
hsa-miR-17 1,603 835 1,039 1,213 935 1,313 650 1,645 1,303 2,689 2,825 
hsa-miR-26b 19,662 23,339 21,834 21,485 8,862 25,726 21,033 22,603 19,095 2,646 1,012 
hsa-let-7g 17,303 18,409 15,822 16,696 9,198 17,300 16,073 16,611 15,576 7,468 6,997 
hsa-miR-199a-3p 13,729 13,044 17,100 14,238 8,640 13,540 11,911 14,504 13,825 2,637 1,650 
hsa-miR-145 12,871 10,978 20,338 18,923 33,129 21,896 20,220 14,934 17,926 130 398 
hsa-miR-1323 7,471 8,094 6,790 9,722 13,136 4,980 7,742 8,853 14,050 120 344 
hsa-miR-145 12,871 10,978 20,338 18,923 33,129 21,896 20,220 14,934 17,926 130 398 
hsa-let-7c 41,779 34,520 31,714 33,236 29,602 32,934 36,362 41,166 33,698 19,542 23,402 
hsa-miR-21 26,068 17,224 24,874 26,178 45,450 19,240 18,898 23,072 30,768 1,273 2,403 
hsa-miR-27a 9,873 10,233 9,910 10,545 3,755 9,024 9,454 10,173 7,340 2,181 1,402 
hsa-miR-1238 41 31 55 31 61 41 36 47 22 126 133 
hsa-miR-516b 3,801 3,602 3,265 4,021 5,226 1,113 3,746 3,322 5,797 66 184 
hsa-miR-424 6,514 4,575 4,459 5,923 3,174 2,917 3,849 7,070 8,222 62 119 
hsa-miR-522 2,192 2,660 1,721 2,380 2,220 1,282 2,366 2,034 3,333 81 317 
hsa-miR-23b 17,195 20,103 19,544 22,609 18,947 25,363 23,866 21,553 21,923 14,634 14,320 
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Object name r n R N mean z-score p-value 
SP1 11 25 1283 19665 1.63107 7.592231 1.66E-07 
SP3 6 25 333 19665 0.423341 8.649733 3.04E-06 
ETS1 5 25 229 19665 0.291126 8.783852 9.01E-06 
ELF2 2 25 4 19665 0.005085 27.99501 9.3E-06 
CTCF 3 25 34 19665 0.043224 14.24285 1.06E-05 
SP4 2 25 28 19665 0.035596 10.42565 0.000575 
SIL 1 25 1 19665 0.001271 28.02856 0.001271 
ZBTB38 1 25 1 19665 0.001271 28.02856 0.001271 
EGR1 3 25 172 19665 0.218663 5.977771 0.001313 
C/EBPalpha 3 25 185 19665 0.235189 5.731578 0.001618 
SRF 3 25 209 19665 0.2657 5.336239 0.00229 
ETS2 2 25 57 19665 0.072464 7.175259 0.002373 
EPAS1 2 25 58 19665 0.073735 7.108625 0.002455 
ZBTB4 1 25 2 19665 0.002543 19.79446 0.002541 
Sin3A 1 25 2 19665 0.002543 19.79446 0.002541 
HOXB5 1 25 2 19665 0.002543 19.79446 0.002541 
AP-2A 3 25 226 19665 0.287312 5.093282 0.002858 
CTIP2 1 25 3 19665 0.003814 16.14192 0.003809 
HOXD3 1 25 3 19665 0.003814 16.14192 0.003809 
PLAG1 1 25 4 19665 0.005085 13.96183 0.005076 
LRRFIP1 1 25 4 19665 0.005085 13.96183 0.005076 
HEY1 1 25 5 19665 0.006356 12.4722 0.006341 
FOXC2 1 25 5 19665 0.006356 12.4722 0.006341 
ELF4 1 25 7 19665 0.008899 10.51449 0.008867 
HOXA9 1 25 7 19665 0.008899 10.51449 0.008867 
Oct-6 1 25 8 19665 0.01017 9.823042 0.010127 
c-Fos 2 25 121 19665 0.153827 4.724569 0.01027 
HOXA13 1 25 9 19665 0.011442 9.249593 0.011386 



























Disease ratio p-value 
Uterine Neoplasms 13 541 9.73E-07 
Uterine Diseases 13 545 1.06E-06 
Leukemia, B-Cell, Chronic 3 24 2.04E-04 
Neoplasms by Site 30 3865 4.45E-04 
Genital Neoplasms, Female 13 981 5.43E-04 
Head and Neck Neoplasms 10 618 6.07E-04 
Neuroblastoma 8 404 6.35E-04 
Neuroectodermal Tumors, 
Primitive, Peripheral 
8 415 7.58E-04 
Thyroid Neoplasms 6 245 1.11E-03 
Adnexal Diseases 13 1072 1.27E-03 
Neuroectodermal Tumors, 
Primitive 
8 486 2.10E-03 
Neoplasms, Neuroepithelial 12 992 2.11E-03 
Leukemia, B-Cell 3 65 3.82E-03 
Papillary Thyroid Carcinoma 3 69 4.53E-03 








Disease ratio p-value 
Hemangioma 14 30 2.17E-23 
Hemangioma, Capillary 9 9 2.44E-20 
Hemangioblastoma 8 8 3.95E-18 
Uterine Diseases 24 545 6.85E-14 
Neoplasms, Vascular Tissue 14 183 2.20E-11 
Uterine Neoplasms 21 541 4.53E-11 
Genital Neoplasms, Female 26 981 5.15E-10 
Adnexal Diseases 26 1072 3.57E-09 
Endocrine Gland Neoplasms 27 1245 1.78E-08 
Head and Neck Neoplasms 19 618 2.38E-08 
Neoplasms by Site 48 3865 6.61E-08 
Thyroid Neoplasms 12 245 1.09E-07 
Digestive System Neoplasms 33 1996 1.59E-07 
Thyroid Diseases 14 372 2.19E-07 
Nervous System Neoplasms 13 326 3.30E-07 
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